Table 2. Meta-analysis results of miR-146a and miR-196a-2 polymorphisms with hepatitis virus-related HCC risk.
| SNP | B vs. A | BB vs. AA | AB vs. AA | BB vs. AA+AB | AB+BB vs. AA | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | P | I2 | Ph | OR (95%CI) | P | I2 | Ph | OR (95%CI) | P | I2 | Ph | OR (95%CI) | P | I2 | Ph | OR (95%CI) | P | I2 | Ph | |
| miR-146a C>G (rs2910164) | ||||||||||||||||||||
| Overall | 1.13 (1.04-1.24) | 0.006 | 36% | 0.14 | 1.28 (1.06-1.55) | 0.01 | 20% | 0.27 | 1.20 (1.04-1.38) | 0.01 | 0% | 0.95 | 1.10 (0.93-1.29) | 0.26 | 35% | 0.15 | 1.22 (1.06-1.39) | 0.004 | 0% | 0.81 |
| HWE | 1.12 (1.02-1.24) | 0.02 | 44% | 0.10 | 1.23(1.01-1.51) | 0.04 | 18% | 0.29 | 1.18 (1.01-1.37) | 0.04 | 0% | 0.95 | 1.07(0.90-1.26) | 0.47 | 36% | 0.15 | 1.19 (1.03-1.37) | 0.02 | 0% | 0.82 |
| Chinese | 1.17 (1.06-1.29) | 0.002 | 39% | 0.15 | 1.32 (1.08-1.62) | 0.007 | 36% | 0.16 | 1.19 (1.03-1.39) | 0.02 | 0% | 0.84 | 1.19 (0.99-1.43) | 0.06 | 32% | 0.20 | 1.23 (1.06-1.41) | 0.005 | 0% | 0.61 |
| HB | 1.20 (1.05-1.36) | 0.006 | 47% | 0.09 | 1.51 (1.14-1.99) | 0.004 | 17% | 0.31 | 1.23 (0.99-1.52) | 0.06 | 0% | 0.84 | 1.18 (0.94-1.46) | 0.15 | 48% | 0.09 | 1.29 (1.06-1.58) | 0.01 | 0% | 0.69 |
| PB | 1.08 (0.95-1.22) | 0.25 | 0% | 0.76 | 1.11 (0.85-1.45) | 0.45 | 0% | 0.64 | 1.17 (0.97-1.42) | 0.10 | 0% | 0.97 | 1.01 (0.79-1.29) | 0.94 | 0% | 0.59 | 1.16 (0.97-1.39) | 0.11 | 0% | 0.93 |
| HBV- | 1.13 (1.03-1.23) | 0.01 | 39% | 0.12 | 1.26 (1.04-1.54) | 0.02 | 10% | 0.36 | 1.20 (1.04-1.39) | 0.01 | 0% | 0.95 | 1.07 (0.91-1.27) | 0.41 | 33% | 0.16 | 1.21 (1.06-1.39) | 0.005 | 0% | 0.81 |
| HCV- | 1.25 (0.89-1.76) | 0.20 | 0% | 0.42 | 1.98 (0.89-4.45) | 0.10 | 0% | 0.39 | 1.18 (0.62-2.23) | 0.62 | 0% | 0.92 | 1.67 (0.75-3.71) | 0.21 | 51% | 0.13 | 1.38 (0.76-2.52) | 0.30 | 0% | 0.97 |
| miR-196a2 C>T (rs11614913) | ||||||||||||||||||||
| Overall | 0.85 (0.74-0.98) | 0.02 | 73% | 0.00 | 0.71 (0.52-0.95) | 0.02 | 75% | 0.00 | 0.84 (0.70-1.01) | 0.07 | 57% | 0.02 | 0.82 (0.68-0.98) | 0.03 | 54% | 0.03 | 0.80 (0.65-0.99) | 0.04 | 71% | 0.00 |
| HWE | 0.88 (0.76-1.01) | 0.07 | 72% | 0.00 | 0.75 (0.55-1.02) | 0.07 | 74% | 0.00 | 0.87 (0.72-1.06) | 0.16 | 55% | 0.03 | 0.85 (0.71-1.02) | 0.08 | 50% | 0.05 | 0.83 (0.67-1.04) | 0.11 | 69% | 0.00 |
| Chinese | 0.85 (0.73-0.99) | 0.04 | 76% | 0.00 | 0.70 (0.50-0.97) | 0.03 | 78% | 0.00 | 0.82(0.67-1.02) | 0.07 | 64% | 0.01 | 0.83 (0.68-1.00) | 0.05 | 56% | 0.04 | 0.79 (0.62-1.00) | 0.05 | 75% | 0.00 |
| HB | 0.83 (0.69-0.99) | 0.04 | 78% | 0.00 | 0.66 (0.45-0.97) | 0.03 | 79% | 0.00 | 0.83 (0.67-1.04) | 0.11 | 60% | 0.02 | 0.77 (0.60-0.99) | 0.04 | 63% | 0.01 | 0.78 (0.60-1.01) | 0.06 | 74% | 0.00 |
| PB | 0.92 (0.70-1.22) | 0.57 | 65% | 0.09 | 0.85 (0.46-1.58) | 0.60 | 68% | 0.08 | 0.88 (0.53-1.45) | 0.62 | 63% | 0.10 | 0.86 (0.71-1.04) | 0.13 | 0% | 0.34 | 0.88 (0.51-1.52) | 0.64 | 71% | 0.06 |
| HBV- | 0.85 (0.73-0.98) | 0.03 | 75% | 0.00 | 0.70 (0.50-0.96) | 0.03 | 77% | 0.00 | 0.83 (0.69-1.01) | 0.06 | 56% | 0.02 | 0.82 (0.67-1.00) | 0.05 | 58% | 0.01 | 0.79 (0.63--0.99) | 0.04 | 71% | 0.00 |
| HCV- | 0.80 (0.65-0.98) | 0.03 | 0% | 0.92 | 0.61 (0.39-0.94) | 0.02 | 0% | 0.93 | 0.82 (0.59-1.12) | 0.21 | 0% | 0.69 | 0.69 (0.47-1.02) | 0.06 | 0% | 1.00 | 0.75 (0.55-1.02) | 0.07 | 0% | 0.72 |
PB: population based; HB: hospital based; HWE: subgroup excluding the studies departing from HWE; HBV-: hepatitis B virus-related HCC; HCV-: hepatitis C virus-related HCC; N: number of samples; A: the major allele; B: the minor allele; OR: odds ratio; CI: confidence interval; Ph: P-value of Q-test for heterogeneity.